{
    "nctId": "NCT04341129",
    "briefTitle": "Abbreviated MRI Protocol: Initial Experience With Dotarem\u00ae (Gadoterate Meglumine)",
    "officialTitle": "Abbreviated MRI Protocol: Initial Experience With Dotarem\u00ae (Gadoterate Meglumine)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms, Breast Diseases, Breast Fibroadenoma, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Compare the diagnostic accuracy of dynamic contrast-enhanced breast MRIs performed with an abbreviated protocol versus a full protocol",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women between the ages of 18-80.\n* Women with diagnostic imaging findings highly suspicious for breast cancer (BI-RADS category 4 or 5) or known breast cancer (BI-RADS category 6). Per BI-RADS lexicon, category 4 lesions carry a malignancy risk of 2-95% and category 5 lesions carry a malignancy risk of \\>95%.\n\nExclusion Criteria:\n\n* Women with a history of adverse reactions to contrast media.\n* Women with GFR below 30 mL/min/1.73m\u00b2.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}